Quick Take
Annovis Bio (OTC:ANVS) intends to raise $10 million in an IPO of its common stock, per an amended registration statement.
The company is developing a pipeline of treatment candidates for the treatment of various neurodegenerative conditions.
ANVS is working on some of the most notoriously difficult areas of disease research and the firm has very little in the way of resources, even after the IPO.
Company & Technology
Berwyn, Pennsylvania-based-based Annovis Bio, previously known as QR Pharma, was founded in 2008 to develop therapeutics for the treatment of neurodegenerative disorders,